A cell therapy program measures three things: the engineered product, what the product does, and what the host does to it. Construct expression and integrity, phenotype, cytotoxic function, expansion, persistence, and the immune response against the construct fall within those three, and few programs need all of them at every timepoint.
These measurements are also a regulatory expectation. FDA’s guidance on the development of chimeric antigen receptor T cell products notes that these are living drugs capable of proliferation, so conventional pharmacokinetic models do not apply, and recommends a sampling schedule with sufficient timepoints during the expansion phase. The guidance notes that persistence may be monitored by measuring levels of transgene and CAR expression, and recommends developing assays to detect humoral or cellular immune responses against the engineered cells, or both. Which readouts a program needs depends on the construct, the delivery method, and the stage, and our scientists settle that with you before samples are collected.

